Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of initiatives meant to call attention to rare diseases as an important public health issue and to improve rare disease education, research, and treatment. Observed annually on the last day of February, Rare Disease Day is an international awareness campaign organized by the patient organization EURORDIS and supported by hundreds of other patient organizations around the world.
February 28, 2013 marks the sixth International Rare Disease Day. This year’s theme, “Rare Disorders without Borders,” emphasizes that international cooperation is essential for fighting diseases that affect only a few people in each country and for which expertise is scarce and scattered. In celebration of this theme, Genzyme is pleased to launch a new website highlighting collaborative activities taking place globally to recognize Rare Disease Day: http://raredisease.genzyme.com.
Genzyme sites around the world are partnering with local patient organizations on a variety of Rare Disease Day activities meant to educate policymakers, medical professionals, patients and caregivers, and the general public and empower them to advocate for those affected by rare diseases. These initiatives include:
In addition, Genzyme is pleased to announce the launch of the third annual Patient Advocacy Leadership Awards (PAL Awards), a global grant program supporting non-profit patient organizations that work on behalf of individuals living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that cause progressive and debilitating health problems. Grants are awarded through a competitive process to organizations that seek funding for innovative programs and projects that improve disease awareness, patient care and support, and education. In 2012, more than 50 patient organizations representing 27 countries submitted proposals, and nine winners chosen by an external review committee received a total of $100,000 from Genzyme.
“Promoting understanding of the journey of those affected by rare diseases while advancing therapies and scientific innovation are core to who Genzyme is, and it is an honor to partner today with advocacy organizations globally to recognize Rare Disease Day,” said Jamie Ring, Genzyme’s Vice President of Global Patient Advocacy for Rare Diseases. “As we begin the PAL Award process again this year, we look forward to seeing how this program can be utilized to support the evolving needs of rare disease advocacy leaders around the world. Together, we recognize that there is still great work – and opportunity – ahead of us.”
More About Genzyme Patient Advocacy Leadership (PAL) Awards
Organizations may apply for a Genzyme PAL Award for programs that support lysosomal storage disorder awareness, advocacy on behalf of patient communities, patient education and patient care, support and communication networks. This grant program is supplemental to Genzyme’s existing grants program and will not replace the contributions made locally each year to support advocacy groups. Proposals will be reviewed by an external review committee. Applications must be received by June 7, 2013 and the award recipients will be announced by September 30, 2013. For more information on the Genzyme PAL Awards program, or to apply for a grant, please visit www.genzymeadvocacyawards.com.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).